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Abstract
Data from high throughput experiments often produce far more results than can ever appear in the main text or tables
of a single research article. In these cases, the majority of new associations are often archived either as supplemental
information in an arbitrary format or in publisher-independent databases that can be difficult to find. These data are
not only lost from scientific discourse, but are also elusive to automated search, retrieval and processing. Here, we use
the nanopublication model to make scientific assertions that were concluded from a workflow analysis of
Huntington’s Disease data machine-readable, interoperable, and citable. We followed the nanopublication guidelines
to semantically model our assertions as well as their provenance metadata and authorship. We demonstrate
interoperability by linking nanopublication provenance to the Research Object model. These results indicate that
nanopublications can provide an incentive for researchers to expose data that is interoperable and machine-readable
for future use and preservation for which they can get credits for their effort. Nanopublications can have a leading role
into hypotheses generation offering opportunities to produce large-scale data integration.
Keywords: Huntington’s disease, Nanopublication, Provenance, Research object, Workflows, Interoperability,
Data integration
Background
The large amount of scientific literature in the field
of biomedical sciences makes it impossible to manually
access and extract all relevant information for a particular
study. This problem is mitigated somewhat by text min-
ing techniques on scientific literature and the availabil-
ity of public online databases containing (supplemental)
data. However, many problems remain with respect to the
availability, persistence and interpretation of the essential
knowledge and data of a study.
Text mining techniques allow scientists to mine rela-
tions from vast amounts of abstracts and extract explicitly
defined information [1] or even implicit information [2,3].
Because most of these techniques are limited to min-
ing abstracts, it is reasonable to assume that information
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such as tables, figures and supplementary information are
overlooked. Moreover, recent attempts to mine literature
for mutations stored in databases, showed that there was
a very low coverage of mutations described in full text and
supplemental information [4].
This is partly remedied by making data public via online
databases. However, this by itself does not guarantee that
data can be readily found, understood and used in com-
putational experiments. This is particularly problematic
at a time when more, and larger, datasets are produced
that will never be fully published in traditional journals.
Moreover, there is no well-defined standard for scien-
tists to get credit for the curation effort that is typically
required to make a discovery and its supporting exper-
imental data available in an online database. We argue
that attribution and provenance are important to ensure
trust in the findings and interpretations that scientists
make public. Additionally, a sufficiently detailed level of
attribution provides an incentive for scientists, curators
and technicians to make experimental data available in
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an interoperable and re-usable way. The Nanopublica-
tion data model [5] was proposed to take all these issues
into consideration. The nanopublication guidelines docu-
ment [5] provides details of the nanopublication schema
and recommendations for constructing nanopublications
from Life Science data. Based on Semantic-web tech-
nology, the nanopublication model is a minimal model
for publishing an assertion, together with attribution and
provenance metadata.
The assertion graph contains the central statement that
the author considers valuable (publishable) and for which
she would like to be cited (attribution). It should be kept
as small as possible in accordance with the guidelines.
The provenance graph is used to provide evidence for the
assertion. It is up to the author to decide howmuch prove-
nance information to give, but in general, more prove-
nance will increase the trustworthiness of the assertion,
and thus the value of the nanopublication. The publication
info graph provides detailed information about the nanop-
ublication itself: creation date, licenses, authors and other
contributors can be listed there. Attribution to curators
and data modelers are part of the nanopublication design
to incentivize data publishing.
We used the nanopublication schema tomodel scientific
results from an in-silico experiment. Previously Beck et al.
[6] used GWAS data stored in the GWAS central database
to model as nanopublications and they demonstrated how
such valuable information can be incorporated within
the Linked Data web to assist the formation of new
hypotheses and interesting findings. In our experiment
we investigated the relation between gene deregulation in
Huntington’s disease and epigenetic features that might
be associated with transcriptional abnormalities (E. Mina
et al., manuscript in preparation).
We show how the results of this case study can be rep-
resented as nanopublications and how this promotes data
integration and interoperability.
Huntington’s Disease as case study for modelling scientific
results into nanopublications
Huntington’s Disease is a dominantly inherited neurode-
generative disease that affects 1 - 10/100.000 individuals
and thus making it the most common inherited neurode-
generative disorder [7]. Despite the fact that the genetic
cause for HD was already identified in 1993, no cure has
yet been found and the exact mechanisms that lead to
the HD phenotype are still not well known. Gene expres-
sion studies revealed massive changes in HD brain that
take place even before first symptoms arise [8]. There is
evidence for altered chromatin conformation in HD [9]
that might explain these changes. We selected to analyse
two datasets that are associated with epigenetic regula-
tion, concerning CpG islands in the human genome [10]
and chromatin marks mapped across nine cell types [11].
Identifying genes that are deregulated in HD and are asso-
ciated with these regions can give insight into chromatin-
associated mechanisms that are potentially at play in this
disease.
Our analysis has been implemented through the use of
workflows using the Taverna workflow management sys-
tem [12,13]. As input we used gene expression data from
three different brain regions from HD affected individuals
and age and sex matched controls [14]. We tested for gene
differential expression (DE) between controls and HD
samples in the most highly affected brain region, caudate
nucleus, and we integrated this data with the two epi-
genetic datasets discussed previously which are publicly
available via the genome browser [15,16].
HD is a devastating disease and no actual cure has
been found yet to treat or slow down disease progres-
sion. Therefore, research on this domain is mainly focus-
ing on the production of new data and investment on
expensive experiments. It is important to realize that shar-
ing information is essential in research for developing
new hypotheses that can tackle difficult use cases such
as HD. Because of the unavailability of previous exper-
iments to be found online using common biomedical
engines, expensive experiments become lost and unnec-
essarily replicated. For example in our case study, we
found that the association that we inferred between the
HTT gene, which mutant form causes Huntington’s Dis-
ease, and BAIAP2, a brain-specific angiogenesis inhibitor
(BAI1)-binding protein, was present in a table in a paper
by Kaltenbach et al. [17]. However, it is not explicitly in
any abstract which makes it hard to retrieve from systems
such as PubMed.
Results and Discussion
Nanopublication model design principles
We decided to model and expose as nanopublications two
assertions from the results of our workflow: 1) differ-
entially expressed genes in HD and 2) genes that over-
lap with a particular genomic region that is associated
with epigenetic regulation. Note that these natural lan-
guage statements would typically be used in a caption
for a figure, table or supplemental information section to
describe a dataset in a traditional publication. Considering
the problems with automatic retrieval and interpretation
of such data, we aim to expose these assertions in a
way that is more useful to other scientists (for example
to integrate our results with their own data). Moreover,
we provide provenance containing the origin and exper-
imental context for the data in order to increase trust
and confidence. Our nanopublications are stored in the
AllegroGraph triple store [18]. The link to the browsable
user interface and the SPARQL endpoint can be found on
the myExperiment link: http://www.myexperiment.org/
packs/622.html. The user can log in and browse through
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the nanopublications by logging in with username “test”
and password “tester”. The queries used in this paper are
stored under the menu “Queries → Saved”.
Assertionmodel
We defined two natural language statements that we wish
to convert to RDF:
“gene X is associated with HD, because it was found to
be deregulated in HD” and “gene Y is associated with a
promoter, and this promoter overlaps with a CpG island
and/or a particular chromatin state”, and we wish to refer
to the experiment by which we found these associations.
We decided to model our results into two nanopublica-
tions. By further subdividing those statements, we see the
RDF triple relations appear naturally:
Nanopublication assertion 1:
1. There is a gene disease association that refers_to
gene X and Huntington’s Disease
Nanopublication assertion 2:
1. Gene Y is associated_with promoter Z
2. Promoter Z overlaps_with a biological regiona
The assertion models are shown in Figure 1 and
Figure 2.
For some of the terms in these statements we found sev-
eral ontologies that defined classes for them. For example,
“promoter”, “gene”, and “CpG island” appear (among oth-
ers) in the following ontologies: NIF Standard ontology
(NIFSTD), NCI Thesaurus (NCI) and the Gene Regu-
lation Ontology (GRO)b. We chose to use NIFSTD for
our case study, because it covers an appropriate domain
and it uses the Basic Formal Ontology (BFO), which can
benefit data interoperability and OWL reasoning (e.g. for
checking inconsistencies).
We chose to use bio2rdf instances for the associated
genes [19] because they provide RDF with resolvable
resource URIs formany different biomedical resources. To
describe the gene-disease association linked with altered
gene expression we used the class with that label from
the SemanticScience Integrated Ontology (SIO) [20]. The
SIO predicate “refers to” was used to associate each dif-
ferentially expressed gene with HD. There were also terms
that we did not find in an available ontology. These were
the ones that described the type of the chromatin state
that a promoter of a gene can be in, “active promoter
state”, “weak promoter state”, “poised promoter state”
and “heterochromatic”. We decided to create our own
classes to describe these terms. Being aware of interoper-
ability issues, we defined them as subtypes of classes in
the Sequence Ontology (SO). We defined the class “chro-
matin_region” as a subclass of “biological_region” in SO.
We defined another class “chromatin_state” as a subclass
of “feature_attribute”. Subclasses of “chromatin_state” are
the states “active_promoter”, “weak_promoter”, “poised_
promoter” and “heterochromatic”, Figure 3. In Table 1
we provide the definition for these classes, the reused SO
ontological terms and their corresponding URIs. We also
defined an object property “has_state” which has domain
chromatin and range “chromatin_state”.
For the predicates we considered the use of the Rela-
tion Ontology. Extending the Relation Ontology with the
appropriate predicates would support interoperability and
reasoning in the long term, because its use of BFO. How-
ever, we found that the OWL domain and range spec-
ifications did not match our statements. Therefore, we
decided to use predicates from the also popular Sequence
Ontology (SO) and Semanticscience Integrated Ontology
(SIO) [20] that also seemed appropriate for our assertions.
This is a typical trade-off between quality and effort that
we expect nanopublishers will have to make frequently.
We can justify this for two reasons: 1) releasing experi-
mental data as linked open data using any standard ontol-
ogy is already an important step forward from current
Figure 1 Differential gene expression assertion model. The template for the differential gene expression assertion. Orange diamonds refer to a
RDF resource that was defined by this nanopublication, whereas the gene (pink diamond) is defined by a bio2rdf resource. The Sequence Ontology
(SO) were used for the predicates refers_to. The classes for Huntington’s disease, gene and gene-disease association linked with altered gene
expression are defined by the nifstd, bio2rdf and SIO ontologies respectively.
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Figure 2 Genomic overlap assertion model. Orange diamonds refer also here to a RDF resource that was defined by this nanopublication,
whereas the gene (pink diamond) is defined by a bio2rdf resource. The classes promoter and biological region were defined by the nifstd ontology.
The Semanticscience Integrated Ontology (SIO) and Sequence Ontology (SO) were used for the predicates overlaps_with and associated_with.
practice and 2) interoperability issues at the ontology level
is a shared responsibility with ontology developers and
curators who provide mappings between ontologies and
with higher level ontologies.
The process of nanopublication modeling can be min-
imized when previous examples are used as templates
for similar data. For instance, the nanopublication mod-
els presented here can serve as templates for exposing
differentially expressed genes in a disease condition. We
demonstrate the reuse of our own template of Figure 2 by
exposing 5 types of nanopublications concerning genomic
overlap. The reuse of templates improves interoperability
of scientific results beyond the interoperability that RDF
already provides. It facilitates crafting assertions while
ensuring that the same URIs are used for the same type of
data.
Provenancemodel
Publishing information is meaningful only if there is
enough supporting information for reproducing them. For
example Ioannidis et al., pointed out that they could not
reproduce the majority of the 18 articles they investigated
describing results from microarray experiments, includ-
ing selected tables and figures [21]. Nanopublication does
not guarantee full reproducibility, but as a model for com-
bining data with attribution and provenance in a digital
format it at least makes it possible to trace the origin
of scientific results. The provenance section of a nanop-
ublication ties the results (the nanopub assertion) to a
description of an experiment and the associated mate-
rials, conditions and methods. The main purpose is to
capture as accurately as possible where the assertion came
from and what the conditions of our experiment were
by aggregating and annotating resources that were used
throughout the experiment.
In our case the experiment is in-silico: a workflow
process that combines existing data sources to expose
new associations. Details and references to the original
datasets, the workflow process itself and the final work-
flow output are interesting provenance as they increase
trust in the assertion and make it possible to trace back
the results of the experiment. An extra benefit of using
Figure 3 Chromatin state classes. Schematic representation of the extension of SO with our own defined classes. In yellow are depicted the SO


































































Table 1 Definition of new classes
Class URI Definition subclass of subclass of URI
chromatin_region biosemantics:chromatin_region A region of chromatin, likely to biological_region so:SO_0001411
be involved in a biological process
chromatin_state biosemantics:chromantin_state Annotation of chromatin states, defined by feature_attribute so:SO_0000733
combinations of chromatin modification patterns
(described in publication by Ernst et al. Nature, 2011)
active_promoter biosemantics:active_promoter Open chromatin region, associated with promoters, chromatin_state biosemantics:chromatin_state
transcriptionally active, defined by the most highly
observed chromatin marks : H3K4me2,H3K4me3, H3K27ac,
H3K9ac
weak_promoter biosemantics:weak_promoter Open chromatin region, associated with promoters, chromatin_state biosemantics:chromatin_state
weak transcription activity, defined by the most highly
observed chromatin marks : H3K4me1, H3K4me2,H3K4me3,
H3K9ac
poised_promoter biosemantics:poised_promoter Open chromatin region, associated with promoters, chromatin_state biosemantics:chromatin_state
described as a bivalent domain that has strong signals
of both active and inactive histone marks. Most highly
observed histone marks: H3K27me3, H3K4me2, H3K4me3
heterochromatic biosemantics:heterochromatic Closed chromatin formation, transcriptionally inactive. chromatin_state biosemantics:chromatin_state
It is associated with none histone marks
Prefix biosemantics: http://rdf.biosemantics.org/ontologies/chromatin#.
Prefix so: http://purl.obolibrary.org/obo/.
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workflows is that provenance information can be auto-
matically generated by the workflow system and addi-
tional tools can be used to associate a workflow with
additional metadata and resources. We used Taverna to
build and execute our workflows [12]. Taverna provides an
option to export the provenance of a workflow execution
in prov-o [22].
Extending nanopublication provenance with the
Research Object model
With the nanopublication provenance model as a starting
point we further enhance provenance with a model that
has been developed for bundling workflows with addi-
tional resources in the form of workflow-centric Research
Objects.
Additional resources may include documents, input and
output data, annotations, provenance traces of past execu-
tions of the workflow, and so on. Research objects enable
in silico experiments to be preserved, such that peers can
evaluate the method that led to certain results, and a
method can be more easily reproduced and reused. Sim-
ilar to nanopublications, the Research object model is
grounded in Semantic Web technologies [23]. It is com-
prised by a core ontology and extension ontologies. The
core ontology reuses the Annotation Ontology (AO) and
the Object Reuse and Exchange (ORE) model to provide
annotation and aggregation of the resources. The exten-
sion ontologies keep track of the results and methods
of a workflow experiment (wfprov), provide the descrip-
tions of scientific workflows (wfdesc) and capture the RO
evolution process (roevo) (Belhajjame K, Zhao J, Carijo
D, Hettne KM, Palma R, Mina E, Corcho O, Gómez-
Pérez JM, Bechhofer S, Klyne G, Goble C: Using a suite
of ontologies for preserving workflow-centric research
objects, accepted for publication Journal of Web Seman-
tics). Research objects extend the already existing func-
tionality of my Experiment packs. We created Research
objects using the Research object repository sandbox,
which offers a user friendly interface for creating Research
objects either by importing an already existing pack from
my Experiment, or uploading a .zip archive or creating a
research object manually [24].
An overview of the connection between the Nanopubli-
cation model and the Research Object is given in Figure 4.
In the nanopublication provenance graph we include a
simple provenance model that describes the context of
the workflow process: in particular the relation of the
nanopublication assertions as the origin of the experi-
ment outputs. Note that the workflow activity links to the
Research Object and each of the input/output entities link
to the corresponding entity in the Research Object. This
way, the nanopublication provenance serves as a proxy
for the Research Object, such that larger nanopublica-
tion collections can be queried without downloading all
Research Objects. Moreover, we increase interoperability
by using the standard Prov-o ontology in the nanopublica-
tion provenance, to which the Research Object ontology
is aligned. Futhermore we increase the semantics of the
input/output entities by using the domain specific Pro-
cess ontology [25]. In summary, the strength of linking
the entities in a nanopublication provenance to a Research
Object, is to augment the experimental context informa-
tion which is key evidence for the statement made in the
assertion. Moreover, this link enables reuse of provenance
information that may be already available. However, we
note that deciding the amount and relevance of prove-
nance information to be included in the nano-publication
remains a decision of the nanopublication author.
Publication info
In the Publication Info section of a nanopublication we
capture details that are required for citation and usage of
the nanopublication itself. The authors of the nanopubli-
cation and possible contributors are described here, and
represented by a unique research identifier to account for
author ambiguity. The timestamp of the nanopublications
creation is also recorded in this part, as well as versioning
details. Finally, information about usage rights and licence
holders is included.
Data integration using nanopublications: assisting drug
target prioritization in HD
By choosing RDF as exchange format for nanopublica-
tions, we also support the data integration features of RDF.
In HD research, diverse working groups recruit a vari-
ety of disciplines that produce data encompassing brain
images, gene expression profiles in brain and periph-
eral tissues, genetic variation, epigenome data, etcetera,
with the common goal to identify biomarkers to moni-
tor disease progression or the effectiveness of therapies.
Nanopublications provide an incentive to expose this
data such that we can more easily integrate them with
each other to assist research in HD by creating novel
hypotheses. These hypotheses can be further tested and
ultimately help the development of effective treatments.
Following standardized templates to model information
ensures data interoperability that can facilitate complex
queries for discovering new information. In addition, the
attached provenance of the assertion will give necessary
information related to the experiment, to ensure trust
but also to be able to reuse the scientific protocol and
replicate the results. Moreover, we note that nanopubli-
cations enable opportunities for data integration beyond
the assertions and the experimental data itself. Since
nanopublication Provenance relates to the methodol-
ogy/protocol that was used as part of an experiment, it
allows us to retrieve all other published nanopublications
based on our workflow, or workflows that are related to it
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Figure 4 Extension of the nanopublication provenance with the Research Object model. The top part of this figure (above the triple line)
shows the Nanopublication consisting of its three constitutive parts: Assertion, Provenance and Publication Info. Below the triple line is the
Workflow pack which contains the Research Object (RO) as well as all the input and output data, workflows and results for the experiment. Note that
the nanopublication and the workflow pack are separate entities that can exist in different locations. The two models are linked by the predicates
shown in the figure as arrows crossing the triple line. In this way the nanopublication re-uses and exposes the detailed (and partially automatically
generated) provenance from the RO. Note that multiple nanopublications can reference the same RO. Not shown in the figure is the possibility for
the RO to link back to the nanopublication as one of the results of the experiment described by the RO.
(e.g. because they use the same kind of input data). Such
(indirect) provenance links greatly improve the discover-
ability of research data. Another option could be to use
the information stored in the Publication Info graph and
retrieve the attribution information for the nanopublica-
tion. This makes it relatively easy to determine the most
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frequently cited nanopublication creators and authors,
for example in order to calculate some kind of impact
factor.
To demonstrate how data integration with nanopubli-
cations can occur in practice we applied simple SPARQL
queries to our local nanopublication store. For example,
to identify differentially expressed genes for which the
promoters are associated both with a CpG island and a
poised chromatin state. The resulted genes can be the
start for further research, as they may be indicators for
an epigenetically mediated gene alteration. The set of the
canned queries are stored in our nanopublication store for
the user to browse and execute (details for accessing the
nanopublication store were mentioned previously in this
paper)
Nanopublications can also facilitate more sophisticated
queries to support data integration. Note that traditional
methods of querying integrated data would typically
require converting data sources to a common format or
database and writing one or more queries and scripts to
solve the actual question. Such an approach can be com-
plex and time-consuming, while the resulting code and
data is not necessarily re-usable to answer other research
questions. Here we show a complex data integration
question that can be answered using a relatively short
SPARQL query.
In this case we would like to identify druggable targets
that target four biological processes that (among others)
are impaired in HD [26,27]. These were the proteaso-
mal protein catabolic process (GO:0010498), autophagy
(GO:0006914), protein folding (GO:0006457) and protein
unfolding (GO:0043335). We identified drug targets by
querying across four different data sources, including
drugbank and pathway data, as schematically shown in
Figure 5. These targets can be a valuable source for fur-
ther investigation in HD research. They can be further
prioritized based on the calculated property value, that is,
the polar surface area (PSA) as being good candidates for
passing the Blood-Brain-Barrier (with PSA <60 2) [28].
Table 2 illustrates drug targets associated with the four
biological processes as for example, we found Imatinib,
associated with the gene ABL1 that targets autophagy and
is known to retard production of beta-amyloid [29]. The
complete list of the drug targets and also the full drug
description can be found at Additional file 1. Figure 6
demonstrates the SPARQL query, separated in different
colours that indicate the different data sources that were
part of this data integration. Due to the size of the datasets
that are involved, this query is not available on the same
end-point as the previous queries. Instead we performed
this query on a temporary instance of a cloud node run-
ning the Virtuoso 7.0 Open Source triple store. We note
that no dataset conversions were necessary: RDF datasets
were downloaded directly from their respective sources
and loaded in our triple store.
At this point it is worth mentioning implementation
decisions that had to be made. First, we decided to include
the GO ontology (rather than the bio2RDF GO data
source) because we wanted to make use of the ontol-
ogy hierarchical structure to obtain all child concepts
Figure 5 Schematic representation of linking data sources for drug target retrieval. A. First we queried the differentially expressed genes
nanopublication to get all gene ids. Further we filtered these ids by querying the biological region nanopublication. Subsequently we queried the
bio2RDF GO annotation dataset to select genes that are involved in the biological processes mentioned in the text. For this gene list we queried
bio2RDF gene information data source to retrieve gene symbols that belong to the human taxonomy, that were used to retrieve the drug target
from bio2RDF drugbank. Last, these drug targets are used to find drugs from the bio2RDF drugbank source. B. The process of querying GO for our
set of biological processes(including the children concepts) and the mapping URI to filter genes from the bio2RDF GO annotation dataset. In this


































































Table 2 Drug target results from the data integration query
Gene GeneSymbol GoTerm Target Drug DrugDescription[3]
http://bio2rdf.org/geneid:25 "ABL1" "autophagy"@en http://bio2rdf.org/drugbank_target:17



















http://bio2rdf.org/geneid:5707 "PSMD1" proteasomal protein catabolic process http://bio2rdf.org/drugbank_target:515 http://bio2rdf.org/drugbank:DB00188 Bortezomib
[3]Although not drugs in the strict sense, these ligands may serve as starting point for (rational) drug design efforts for these targets.
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Figure 6 Drug target retrieval SPARQL query. A. SPARQL query for retrieving and adding GO terms from the GO ontology to our local graph.
B. The example SPARQL query that retrieves drug targets and drug names from Drugbank that are associated with the genes that we identified as
differentially expressed in Huntington’s Disease and overlap with CpG islands. red: our local nanopublication store; blue: the mapping URI; green:
bio2RDF data sources.
associated with the GO concepts of interest. This is some-
thing that is not readily possible with the bio2RDF data
source, because it does not include the GO ontology
itself. Secondly, we had to perform a mapping between
the GO ontology and the bio2RDF data source because
they are using different URIs to represent the same GO
term. Figure 5B depicts this part of the query. Although
it is possible to execute this as part of the main integra-
tion query (Figure 6B), experimentation showed that our
particular triple store has better performance when the
URI mappings were stored first. In Figure 6A we present
the original SPARQL query we created to insert the GO
terms and their corresponding subclassses from the GO
ontology to the graph stored locally.
In the end, the query ran within 15 seconds and
retrieved the results as given in Table 2. A detailed dis-
cussion of the results is out of the scope of this paper.
However, we note that the effort required to integrate
these data is relatively minimal: aside from loading the
data sources, it approximately takes only an hour to con-
struct the query. Moreover, as is indicated in Figure 6,
the query itself is modular: consisting of specific sections
related to specific datasets. Therefore extending the query
to include other datasets is not very difficult.
Conclusion
To date there is an enormous amount of valuable infor-
mation that has been produced by expensive experiments,
Mina et al. Journal of Biomedical Semantics 2015, 6:5 Page 11 of 12
http://www.jbiomedsem.com/content/6/1/5
but remains lost in databases and other repositories that
are not easily accessed or processed automatically. This
results not only in replicating experiments that have
already been performed, but also in preventing all those
associations from being tested or reused for building new
hypotheses. This paper presents a method that enables
life scientists to (i) expose the results from an analysis as
scientific assertions, (ii) claim these as their contribution
and (iii) provide provenance of the analysis as reference
for the claimed assertions. We demonstrated an exam-
ple from research in Huntington’s Disease. In addition, we
presented examples of nanopublication integration in the
context of HD, and examples of how nanopublications can
facilitate more sophisticated queries, integrating datasets
from different research domains. The models for these
nanopublications can be used as templates to create simi-
lar nanopublications, while the extension to the ROmodel
can also be used to aggregate resources from other exper-
iments that do not involve scientific workflows. Nanop-
ublication provides an incentive for scientists to expose
the results from individual experiments and make them
available for future exploitation. This ultimately facilitates
research across datasets that we anticipate will provide
new insights about disease mechanisms. Research can
become more efficient and go beyond monolithic journal
publication [30].
Endnotes
a in our case the biological region is: CpG island or one
of the chromatin states, active/weak/poised promoter or
heterochromatic (see Figure 1 and Figure 2).
bAll ontologies mentioned in this paper are available
through http://bioportal.bioontology.org/ontologies.
Additional file
Additional file 1: Drug target information. This document contains the
extended list that resulted from the data integration query concerning
drug target information for the four biological processes.
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